AARTIDRUGS

Aarti Drugs Financial Results

₹416.75-2.81%
Market cap
₹3,804 crore
P/E
19.9
P/B
2.46
ROE
13.4%
Dividend yield
1.20%

For the year ended Mar 2019, Aarti Drugs reported revenue of ₹1,561 crore and net profit of ₹90 crore, against ₹1,806 crore and ₹141 crore a year earlier.

Aarti Drugs annual profit and loss

Financial years, newest first. TTM = trailing twelve months.

Aarti Drugs annual profit and loss (₹ crore)
ItemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue1,5611,8062,1552,4892,7062,5092,3692,5212,678
Expenses1,3541,5441,7182,1592,3892,1802,0702,2012,344
Operating profit207262437329317329299320333
Operating margin %13%14%20%13%12%13%13%13%12%
Other income66511-9-94-91
Interest403423213334363434
Depreciation434950505051566771
Profit before tax131185369270224236212211229
Tax %31%24%24%24%26%27%21%8%17%
Net profit90141280205166172168195191
EPS (₹)9.6915.2730.2822.1417.9618.6518.4221.3620.95
Dividend payout %—————————

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Aarti Drugs financial results — frequently asked questions

What is Aarti Drugs' annual revenue and net profit?

For the financial year ended Mar 2019, Aarti Drugs' revenue was ₹1,561 crore and net profit ₹90 crore; net profit fell 36.17% from ₹141 crore in Mar 2020.

How fast has Aarti Drugs grown over three years?

From Mar 2022 to Mar 2019, Aarti Drugs' revenue grew at a compound annual rate of -14.4% and net profit at -24.0%. Past growth does not indicate future results.

What is the EPS of Aarti Drugs?

Annual EPS for Mar 2019 was ₹9.69.

Are these figures consolidated or standalone?

They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.

Same Data For Peers

Trade Aarti Drugs With ATS

Track AARTIDRUGS live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.